CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+16%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$324M
AUM Growth
+$28.5M
(+9.6%)
Cap. Flow
-$70.4K
Cap. Flow
% of AUM
-0.02%
Top 10 Holdings %
Top 10 Hldgs %
32.96%
Holding
465
New
18
Increased
159
Reduced
244
Closed
13
Top Buys
| 1 |
Vanguard World Funds Extended Duration ETF
EDV
|
$3.28M |
| 2 |
Tesla
TSLA
|
$2.24M |
| 3 |
Apple
AAPL
|
$2.14M |
| 4 |
Meta Platforms (Facebook)
META
|
$2.1M |
| 5 |
Vaxcyte
PCVX
|
$2M |
Top Sells
| 1 |
iQIYI
IQ
|
$4.85M |
| 2 |
Amazon
AMZN
|
$4.7M |
| 3 |
Airbnb
ABNB
|
$3.2M |
| 4 |
Analog Devices
ADI
|
$2.94M |
| 5 |
KE Holdings
BEKE
|
$1.93M |
Sector Composition
| 1 | Technology | 41.8% |
| 2 | Consumer Discretionary | 21.38% |
| 3 | Healthcare | 19.26% |
| 4 | Communication Services | 6.74% |
| 5 | Financials | 4.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
MaxCyte
MXCT
$150M
| $6.2K | ﹤0.01% |
1,351
-31
| -2% | -$142 |
|
352
Stoke Therapeutics
STOK
$1.13B
| $6.16K | ﹤0.01% |
579
+44
| +8% | +$468 |
|
353
Fate Therapeutics
FATE
$116M
| $6.14K | ﹤0.01% |
1,290
-40
| -3% | -$190 |
|
|
ICPT
354
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $6.05K | ﹤0.01% |
547
-14
| -2% | -$155 |
|
|
AMRN
355
Amarin Corp
AMRN
$311M
| $6K | ﹤0.01% |
252
-7
| -3% | -$167 |
|
356
Enanta Pharmaceuticals
ENTA
$189M
| $5.91K | ﹤0.01% |
276
-7
| -2% | -$150 |
|
357
Repare Therapeutics
RPTX
$72.6M
| $5.84K | ﹤0.01% |
552
-18
| -3% | -$190 |
|
|
PETQ
358
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $5.8K | ﹤0.01% |
382
-10
| -3% | -$152 |
|
359
Lexicon Pharmaceuticals
LXRX
$396M
| $5.69K | ﹤0.01% |
2,485
-72
| -3% | -$165 |
|
360
Cullinan Oncology
CGEM
$413M
| $5.55K | ﹤0.01% |
516
-17
| -3% | -$183 |
|
361
Erasca
ERAS
$457M
| $5.45K | ﹤0.01% |
1,976
+109
| +6% | +$301 |
|
362
Evolus
EOLS
$495M
| $5.42K | ﹤0.01% |
746
-16
| -2% | -$116 |
|
363
Scholar Rock
SRRK
$3.02B
| $5.37K | ﹤0.01% |
712
+12
| +2% | +$90 |
|
364
Coherus Oncology, Inc. Common Stock
CHRS
$150M
| $5.27K | ﹤0.01% |
1,233
+179
| +17% | +$764 |
|
365
Ocular Therapeutix
OCUL
$2.37B
| $5.24K | ﹤0.01% |
1,016
-27
| -3% | -$139 |
|
366
MeiraGTx Holdings
MGTX
$619M
| $5.24K | ﹤0.01% |
779
+122
| +19% | +$820 |
|
367
Arbutus Biopharma
ABUS
$805M
| $5.01K | ﹤0.01% |
2,177
+57
| +3% | +$131 |
|
368
Vanda Pharmaceuticals
VNDA
$272M
| $4.96K | ﹤0.01% |
753
-16
| -2% | -$105 |
|
|
ALLK
369
DELISTED
Allakos
ALLK
| $4.94K | ﹤0.01% |
1,134
-20
| -2% | -$87 |
|
370
HUTCHMED
HCM
$2.74B
| $4.94K | ﹤0.01% |
412
-43
| -9% | -$516 |
|
371
Texas Roadhouse
TXRH
$11.2B
| $4.94K | ﹤0.01% |
+44
| New | +$4.94K |
|
372
Mersana Therapeutics
MRSN
$34M
| $4.93K | ﹤0.01% |
60
+1
| +2% | +$82 |
|
373
Castle Biosciences
CSTL
$683M
| $4.8K | ﹤0.01% |
350
-10
| -3% | -$137 |
|
374
Generation Bio
GBIO
$40.3M
| $4.74K | ﹤0.01% |
86
+5
| +6% | +$275 |
|
375
Kodiak Sciences
KOD
$556M
| $4.73K | ﹤0.01% |
686
-22
| -3% | -$152 |
|